Longitudinal alterations of the gut mycobiota and microbiota on COVID-19 severity.
COVID-19
Candida
Enterococcus
Gut
Microbiota
Mycobiota
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
24 Jun 2022
24 Jun 2022
Historique:
received:
25
12
2021
accepted:
01
04
2022
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
29
6
2022
Statut:
epublish
Résumé
The impact of SARS-CoV-2 infection on the gut fungal (mycobiota) and bacterial (microbiota) communities has been elucidated individually. This study analyzed both gut mycobiota and microbiota and their correlation in the COVID-19 patients with severe and mild conditions and follow-up to monitor their alterations after recovery. We analyzed the gut mycobiota and microbiota by bacterial 16S and fungal ITS1 metagenomic sequencing of 40 severe patients, 38 mild patients, and 30 healthy individuals and reanalyzed those of 10 patients with severe COVID-19 approximately 6 months after discharge. The mycobiota of the severe and mild groups showed lower diversity than the healthy group, and in some, characteristic patterns dominated by a single fungal species, Candida albicans, were detected. Lower microbial diversity in the severe group was observed, but no differences in its diversity or community structure were detected between the mild and healthy groups. The microbiota of the severe group was characterized by an increase in Enterococcus and Lactobacillus, and a decrease in Faecalibacterium and Bacteroides. The abundance of Candida was positively correlated with that of Enterococcus in patients with COVID-19. After the recovery of severe patients, alteration of the microbiota remained, but the mycobiota recovered its diversity comparable to that of mild and healthy groups. In mild cases, the microbiota is stable during SARS-CoV-2 infection, but in severe cases, alterations persist for 6 months after recovery.
Sections du résumé
BACKGROUND
BACKGROUND
The impact of SARS-CoV-2 infection on the gut fungal (mycobiota) and bacterial (microbiota) communities has been elucidated individually. This study analyzed both gut mycobiota and microbiota and their correlation in the COVID-19 patients with severe and mild conditions and follow-up to monitor their alterations after recovery.
METHODS
METHODS
We analyzed the gut mycobiota and microbiota by bacterial 16S and fungal ITS1 metagenomic sequencing of 40 severe patients, 38 mild patients, and 30 healthy individuals and reanalyzed those of 10 patients with severe COVID-19 approximately 6 months after discharge.
RESULTS
RESULTS
The mycobiota of the severe and mild groups showed lower diversity than the healthy group, and in some, characteristic patterns dominated by a single fungal species, Candida albicans, were detected. Lower microbial diversity in the severe group was observed, but no differences in its diversity or community structure were detected between the mild and healthy groups. The microbiota of the severe group was characterized by an increase in Enterococcus and Lactobacillus, and a decrease in Faecalibacterium and Bacteroides. The abundance of Candida was positively correlated with that of Enterococcus in patients with COVID-19. After the recovery of severe patients, alteration of the microbiota remained, but the mycobiota recovered its diversity comparable to that of mild and healthy groups.
CONCLUSION
CONCLUSIONS
In mild cases, the microbiota is stable during SARS-CoV-2 infection, but in severe cases, alterations persist for 6 months after recovery.
Identifiants
pubmed: 35751044
doi: 10.1186/s12879-022-07358-7
pii: 10.1186/s12879-022-07358-7
pmc: PMC9233337
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
572Subventions
Organisme : Japan Agency for Medical Research and Development
ID : 20fk0108265
Organisme : AMED-CREST grants
ID : 18gm1010005
Informations de copyright
© 2022. The Author(s).
Références
Vaccines (Basel). 2022 Feb 10;10(2):
pubmed: 35214731
Nat Med. 2021 Apr;27(4):626-631
pubmed: 33692530
Appl Environ Microbiol. 2004 Jan;70(1):167-73
pubmed: 14711639
Virus Res. 2020 Aug;285:198018
pubmed: 32430279
Front Immunol. 2019 May 28;10:1142
pubmed: 31231363
Cell Host Microbe. 2014 Jan 15;15(1):95-102
pubmed: 24439901
Gut Microbes. 2013 Sep-Oct;4(5):409-15
pubmed: 23941906
Genome Biol. 2011 Jun 24;12(6):R60
pubmed: 21702898
Gut. 2021 Feb;70(2):276-284
pubmed: 32690600
Commun Biol. 2021 Apr 13;4(1):480
pubmed: 33850296
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Front Nutr. 2021 May 13;8:638825
pubmed: 34055851
Clin Microbiol Infect. 2021 Jan 8;:
pubmed: 33429028
Microb Pathog. 2018 Apr;117:191-199
pubmed: 29477742
Science. 2020 Apr 24;368(6489):365-366
pubmed: 32327584
Gastroenterology. 2020 Oct;159(4):1302-1310.e5
pubmed: 32598884
Front Microbiol. 2017 Feb 15;8:238
pubmed: 28261190
Clin Infect Dis. 2021 Nov 2;73(9):e2838-e2839
pubmed: 33124650
Clin Infect Dis. 2022 Mar 9;74(5):802-811
pubmed: 34145450
Gastroenterology. 2022 Feb;162(2):548-561.e4
pubmed: 34687739
J Fungi (Basel). 2021 Apr 08;7(4):
pubmed: 33917967
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Curr Opin Virol. 2021 Aug;49:21-26
pubmed: 34000641
Biol Blood Marrow Transplant. 2020 May;26(5):1028-1033
pubmed: 32018061
Gastroenterology. 2020 Sep;159(3):944-955.e8
pubmed: 32442562
PLoS Pathog. 2019 Apr 22;15(4):e1007717
pubmed: 31009520
Clin Infect Dis. 2020 Dec 17;71(10):2669-2678
pubmed: 32497191
Gut. 2021 Apr;70(4):698-706
pubmed: 33431578
PLoS One. 2020 Sep 18;15(9):e0239403
pubmed: 32946527
Mediators Inflamm. 2020 Apr 4;2020:9560684
pubmed: 32322167
Int J Food Microbiol. 2008 Sep 1;126(3):291-301
pubmed: 17889954